GCP
SMMT icon

GSA Capital Partners’s Summit Therapeutics SMMT Stock Holding History

GSA Capital Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,963
Closed -$361K – 2053
2025
Q2 		$361K Buy
16,963
+1,312
+8% +$29.9K 0.03% 1147
2025
Q1 		$302K Sell
15,651
-22,831
-59% -$458K 0.03% 1149
2024
Q4 		$687K Buy
+38,482
New +$746K 0.05% 671
2023
Q1 		– Sell
-12,500
Closed -$53K – 1903
2022
Q4 		$53K Buy
+12,500
New +$22.7K 0.01% 1356

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

GSA Capital Partners's SMMT Position: Q3 2025 in Review

GSA Capital Partners sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 16,963 shares — an estimated $361K sold.

GSA Capital Partners first reported a position in SMMT in Q4 2022 and held it in 4 quarters. The position peaked at $687K in Q4 2024. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • GSA Capital Partners reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 16,963 Summit Therapeutics shares in Q3 2025, an estimated $361K.
  • GSA Capital Partners first reported a position in Summit Therapeutics in Q4 2022 and held it in 4 quarters.
  • GSA Capital Partners's Summit Therapeutics position peaked at $687K in Q4 2024.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.